In This Section

Companion Animals in the Cancer Therapeutic Development Pipeline

Sunday April 07, 2019

3:00 pm - 5:00 pm Eastern Time (ET)

Room W205 A


Chair :

Daniel Gustafson
Colorado State University

Naturally-occurring cancers in pet animals are becoming increasingly recognized as an opportunity to advance studies in cancer drug and therapeutic development. The field of comparative oncology studies and treats canine and feline cancers both for therapeutic intent in the animal itself as well as a research tool to further understanding of human cancer and cancer therapies. This symposium will provide an introduction to the field of comparative oncology through discussions of the mutational landscape and driver mutations present in canine cancers, and how therapeutic trials in pet dogs can generate pharmacodynamic and pharmacokinetic information beneficial to the drug development process.


Daniel Gustafson - Colorado State University

Introduction to Comparative Oncology

Matthew Bailey - Foundation for Biomedical Research

Perceptions of Animal Research: Challenges and Opportunities

Dawn Duval - Colorado State University

Mutational Landscape of Spontaneous Canine Tumors and Investigation of Potential Driver Mutations and Drug Sensitivity

David Vail - University of Wisconsin-Madison

Molecular Targets and Pharmacodynamic Driven Drug Trials in Companion Animals

Luke Wittenburg - University of California, Davis

Pharmacokinetic Principles and Considerations for Companion Animal Drug Trials

Last Updated: August 15, 2019
Key Dates
April 6

ASPET Business Meeting and Awards Presentation

April 6-9

ASPET Annual Meeting at EB 2019